I don't think FDA approval is that big an incentive for a large company to buy Titan, if anyone were to buy them. The technology is pretty sound, and the IP appears to be locked down pretty tightly as well. I don't believe the FDA concerns themselves with patent infringement issues so much as safety and efficacy. Given the understanding they all would have regarding the technology, any company could be interested in buying us out at any time because the risk items (technology and IP protection) are pretty well taken care of already, and safety and efficacy are not an issue for any organization willing to put the resources into finalizing development to meet these criteria. The efficacy is inherent in the design and is apparent. Safety includes things like redundant sub-systems where needed, maybe dual algorithms with comparisons before allowing any potentially critical movement, and regulatory requirements such as EMI/EMC/ESD compliance etc. Whether Titan completes all these aspects (majority of them must already be done to head to a clinical site like Nicholson Center) or if someone else buys them, it just means a sugar daddy is footing the rest of the bills to completion. If anything, FDA approval disincentivizes someone from buying them because Titan can demand much more money at that stage, plus they would be starting their marketing under the Titan name. If they are to be bought, the buying company would want to get marketing up and running with their own name and with their own pre-established distribution chains - much easier than transitioning and having to swallow the additional stranded costs.
